CD3+, CD4+, and CD20+ lymphocytes were expressed in all three prostate regions examined in the study—benign biopsy (BBG), tumor‐adjacent normal glands (TAG), and malignant tumor glands (MTG) (Figure S1). This evidence concerns the gene CD4 and neoplasm.